Piezo Motion partners with Indoles Precision, a company in The Netherlands, to deliver affordable motion control and micro-precision motors into Europe 

LAKEWOOD RANCH, Fla. (August 3, 2022) –– Piezo Motion, a Brain Scientific (OTCQB:BRSF) company, and Indoles Precision, a platform for precise motion and positioning applications, today announce a partnership. Indoles Precision BV, based in Utrecht, The Netherlands, will support Piezo Motion’s revolutionary technology in the Netherlands, Belgium, Luxembourg, Denmark, Sweden, Holland, and Finland. 

Piezo Motion’s unique technology will provide precision motor and motion control solutions to Indoles Precision’s customers that specialize in electronic components, modules and systems, and optimum technical services. Piezo Motion’s multifaceted rotary and linear motors are built with technology that provides a stable, accurate motor designed specifically for OEMs that require ultimate speed, size, and accuracy. 

“Indoles Precision is excited to partner with Piezo Motion Corp,” said Hans van Winden, director at Indoles Precision. “We believe the innovative Piezo Motion products offer unique drive solutions in terms of precision, compactness and cost-effectiveness that allow for cutting-edge end-customer products.” 

Piezo Motion motors are used globally for a variety of applications. These include laboratory instruments, biomedicine, optics, semiconductors, nanotechnology, and industrial electronic and automotive systems, along with an expanding portfolio of products that combine high performance with dramatically lower cost over conventional piezo solutions. 

“We continue to see high demand for our innovative motion technologies,” said Hassan Kotob, Chairman and CEO of Brain Scientific. “Our precision motors continue to displace traditional DC motors, and we are excited to partner with Indoles Precision and bring our cutting-edge products to their customers in Europe.” 

About Piezo Motion 

Piezo Motion (piezomotion.com), a Brain Scientific company, is a leader in precision motor technology with multimillion-dollar investments in research and development of affordable piezoelectric motors to meet, and exceed, the needs of today’s global markets. The company is committed to the development of innovative technology and motion products that enhance functionality in a multitude of applications. The company works with startups, OEMs, research institutions and industrial companies from around the world, empowering the visionaries behind their products. 

About Brain Scientific  

Brain Scientific (brainscientific.com) is a medical technology company with multiple patents and FDA-cleared products. Brain Scientific is committed to developing next-gen solutions that advance the future of neurodiagnostic and OEM medical devices. Brain Scientific has two product lines covering neurology and precision motion. The NeuroCap and NeuroEEG are smart neurological diagnostic devices that simplify administration, shorten scan time, and cut costs. The Piezo Motion product line consists of ultra-efficient compact precision motors that will drive the next generation of medical devices. To learn more about Brain Scientific’s corporate strategy, products, or investor relations, please visit brainscientific.com. 

About Indoles Precision B V 

Indoles Precision (indoles-precision.nl), based in Utrecht, The Netherlands, is a platform for precise motion and positioning applications. The company supports customers as an intermediate with know-how and care. Indoles Precision is convinced that a win-win collaboration on a human scale is the basis for sustainable relationships between all stakeholders. Indoles Precision believes in sustainable relationships and that win-win situations form the fundamental basis for this: a solution is only successful if it works for everyone. People are always at the centre of attention, because even though high-tech solutions are concerned, it is ultimately determined at the human level whether long-term cooperation is a success. 

Forward-Looking Statements 

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of EEG products and services and piezo motor technology; (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items; (iii) the company’s future financial performance; (iv) the successful integration of Piezo Motion with and into Brain Scientific; and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, over many of which the company has no control. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the company’s inability to obtain additional financing; the significant length of time and resources associated with the development of products and related insufficient cash flows and resulting illiquidity; the company’s inability to expand its business; significant government regulation of medical devices and the healthcare industry; lack of product diversification; volatility in the price of the company’s raw materials; and the failure to implement the company’s business plans or strategies. Some of these and other factors are identified and described in more detail in the company’s filings with the SEC. The company does not undertake to update these forward-looking statements.